Akebia Therapeutics said Tuesday that its experimental anemia pill achieved the primary efficacy and heart-safety goals in two pivotal Phase 3 clinical trials involving patients with chronic kidney disease requiring dialysis.

The oral medicine, called vadadustat, represents a new, more convenient and potentially safer way to treat anemia — a common condition for patients with chronic kidney disease. Injectable anemia drugs from Amgen and Johnson & Johnson are the standard treatment today. Those products generate billions of dollars in sales annually but must be used carefully because they carry significant heart-safety risks.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy